Can inoculation with diazotrophic bacteria decrease the productivity loss of defoliated Vigna unguiculata (L.) Walp? by Caliane da S. Braulio (10469226)

Inhibition of <i>miR-750</i> led to decreased egg production in female schistosomes. by Pengfei Du (513926)

“…<p>A) RT-qPCR analysis of <i>miR-750</i> expression in female and male schistosomes. ns means no statistically significant difference. …”

Combined decitabine and Taxol decreases MCF-7/Taxol cells proliferation and can improve their chemosensitivity. by Weihua Gong (471435)

AIM-100 reduces dsRNA silencing in body wall muscle and decreases DA neurodegeneration. by Anthony L. Gaeta (13272609)

VMH Menin knockdown induced decreased hippocampal D-serine levels and impaired synaptic functions. by Lige Leng (14803241)

Decreased expression of proteins involved in mitochondrial dynamics and regulation of oxidative stress in prion infected mice. by Anne Ward (334296)

CR increases ROS and decreases the mtDNA copy number in MLH1 deficient cells. by Berna Somuncu (12770334)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)